drugset / Trial / NCT03071679

Topical Challenge With Omiganan and Imiquimod in Healthy Volunteers

NCT03071679

Phase 1 Completed 16 enrolled Maruho Co., Ltd.
RandomizedFactorialQuadruple-blindOther

Summary

This study has a randomized, evaluator-blinded, vehicle- controlled study to assess the pharmacodynamics of omiganan and omiganan with imiquimod in healthy volunteers.

Timeline

Start
2017-02-06
Primary completion
2017-03-07
Completion
2017-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Imiquimod Other / unclassified 15 mg Topical
Subject Omiganan Protein / enzyme biologic 1 % Topical
Subject Omiganan Protein / enzyme biologic 2.5 % Topical

Indications

No indication recorded.